<p>Vor Biopharma Inc. has approved a stock option repricing for certain outstanding options under its 2021 Equity Incentive Plan and 2023 Inducement Plan, reducing the exercise price to $8.18 per share, the closing price on December 5, 2025. Notably, Chief Financial Officer Sandy Mahatme’s previously granted 694,137 restricted stock units were cancelled and replaced with an option to purchase 1,388,274 shares at an initial exercise price of $17.80 per share, which will automatically adjust to $8.18 per share for exercises beginning December 5, 2027 or upon a Change in Control. President and CEO Jean-Paul Kress also had 4,164,831 options repriced from an original exercise price of $17.80. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-311957), on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

<p>Vor Biopharma Inc. has repriced stock options for executives, reducing the exercise price to $8.18 per share. CFO Sandy Mahatme's restricted stock units were replaced with options to purchase shares at an adjusted price. CEO Jean-Paul Kress's options were also repriced. This adjustment is part of the company's 2021 Equity Incentive Plan and 2023 Inducement Plan.</p>

Vor Biopharma Cuts Stock Option Exercise Price to $8.18 for Executives